Rani Therapeutics Holdings, Inc. (RANI)

NGM – Real vaqt narxi. Valyuta: USD

1.10

+0.03 (2.80%)

Yopilishda: May 12, 2026, 4:00 PM EDT

1.09

-0.01 (-0.91%)

Bozor oldidan: May 13, 2026, 4:11 AM EDT

12.05.2026

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the company's management team will participate in the upcoming H.C.

09.04.2026

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Dr. Sara Kenkare-Mitra as a Strategic Advisor. Dr. Kenkare-Mitra brings nearly three decades of experience in biologics and small molecule drug discovery and development, with a proven track record of global regulatory approvals and commercial launches across oncology, immunology, neurodegeneration, ophthalmology, and respiratory diseases.

27.03.2026

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

26.03.2026

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus – - Announced preclinical data demonstrating successful oral delivery of semaglutide via RaniPill® – - Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 – - Initiated Phase 1 Study of RT-114 RaniPill® for the treatment of obesity in collaboration with ProGen – - Conference call today at 4:30 p.m. ET / 1:30 p.m.

25.03.2026

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Jesper Høiland as Head of Strategy.

19.03.2026

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani's management team will host a conference call and webcast beginning at 4:30 p.m. ET.

28.01.2026

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.

Videolar

No Data

There is no data to display

Press-relizlar

09.04.2026

Rani Therapeutics Holdings, Inc. (RANI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Videolar

No Data

Press-relizlar

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Videolar

No Data

Press-relizlar

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Search stocks

Rani Therapeutics Holdings, Inc. (RANI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Rani Therapeutics Holdings, Inc. (RANI)

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Videolar

No Data

Press-relizlar

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Videolar

No Data

Press-relizlar

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer